Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682522 · ClinicalTrials.gov registry record · Phase 4
Flagyl Microbiome in Crohn's Disease
A Phase 4 study of Crohn Disease, sponsored by University of Louisville.
- Completed
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04682522: Completed Phase 4 study of Crohn Disease, sponsored by University of Louisville.
NCT04682522 is a Phase 4 study of Crohn Disease that has completed, run by University of Louisville. The registered enrollment target is 4 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04682522, a Phase 4 study of Crohn Disease, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the types of bacteria in the colon before and after colon resection surgery. The investigator will also compare standard post-operative antibiotic treatment to flagyl (metronidazole) treatment post-operatively to see if giving the antibiotic, decreases the incidence of return of Crohn's disease.
Primary Outcome
Any change in the types of bacteria in the gut during the study period. This will be done by doing genetic analysis of differences in stool over time.
Conditions Studied
Interventions
- DRUG Metronidazole Oral
Study Locations (1)
Kentucky
- University Surgical Associates - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-03-21 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 4 |
What the finished NCT04682522 record still lists
NCT04682522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which Metronidazole Oral is the first listed.
NCT04682522 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04682522 about?
NCT04682522 is a clinical study titled "Flagyl Microbiome in Crohn's Disease". This study will compare the types of bacteria in the colon before and after colon resection surgery. The investigator will also compare standard post-operative antibiotic treatment to flagyl (metronidazole) treatment post-operatively to see if giving the antibiotic, decreases the incidence of return...
What is the current status of trial NCT04682522?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2021-03-21. Estimated completion is 2023-08-15.
What conditions does trial NCT04682522 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT04682522?
The interventions under investigation include: Metronidazole Oral (DRUG).
Who is sponsoring clinical trial NCT04682522?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04682522 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04682522's enrollment target sits among peer trials
4 72nd of 71 the lowest of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
-
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
RECRUITING · Phase 4
-
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RECRUITING · Phase 4
-
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
ACTIVE NOT RECRUITING · Phase 4
-
Triple Combination Therapy in High Risk Crohn's Disease (CD)
COMPLETED · Phase 4
-
Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI